Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 45719W205 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Perceptive Advisors LLC
13G/A
Amendment 3
|
6.9% |
8/14/2026
Event 6/30/2026
|
|
| Perceptive Advisors LLC | 6.9% | ||
| Joseph Edelman | 6.9% | ||
| Perceptive Life Sciences Master Fund, Ltd. | 6.9% | ||
|
Nantahala Capital Management, LLC
13G/A
Amendment 2
|
4.3% |
8/14/2026
Event 6/30/2026
|
|
| Nantahala Capital Management, LLC | 4.3% | ||
| Wilmot B. Harkey | 4.3% | ||
| Daniel Mack | 4.3% | ||
|
Sands Capital Life Sciences Pulse Fund II, L.P.
13G/A
Amendment 3
|
9.3% |
8/13/2026
Event 6/30/2026
|
|
| Sands Capital Life Sciences Pulse Fund II, L.P. | 9.3% | ||
| Sands Capital Alternatives, LLC | 9.3% | ||
| Sands Frank M. | 9.3% | ||
|
RA Capital Management, L.P.
13G/A
Amendment 1
|
9.9% |
7/31/2026
Event 7/29/2026
|
|
| RA Capital Management, L.P. | 9.9% | ||
| Peter Kolchinsky | 9.9% | ||
| Rajeev Shah | 9.9% | ||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||
| BlackRock, Inc. 13G | 5.9% |
7/28/2026
Event 6/30/2026
|
|
|
RA Capital Management, L.P.
13G
|
15.9% |
7/17/2026
Event 7/10/2026
|
|
| RA Capital Management, L.P. | 15.9% | ||
| Peter Kolchinsky | 15.9% | ||
| Rajeev Shah | 15.9% | ||
| RA Capital Healthcare Fund, L.P. | 15.9% | ||
|
Commodore Capital LP
13G/A
Amendment 1
|
9.9% |
5/15/2026
Event 3/31/2026
|
|
| Commodore Capital LP | 9.9% | ||
| Commodore Capital Master LP | 9.9% | ||
| Robert Egen Atkinson | 9.9% | ||
| Michael Kramarz | 9.9% | ||
|
Trails Edge Capital Partners, LP
13G/A
Amendment 1
|
6.1% |
5/15/2026
Event 3/31/2026
|
|
| Trails Edge Capital Partners, LP | 6.1% | ||
| Trails Edge Biotechnology Master Fund, LP | 6.1% | ||
| Ortav Yehudai | 6.1% | ||
|
Perceptive Advisors LLC
13G/A
Amendment 2
|
8.9% |
5/15/2026
Event 3/31/2026
|
|
| Perceptive Advisors LLC | 8.9% | ||
| Joseph Edelman | 8.9% | ||
| Perceptive Life Sciences Master Fund, Ltd. | 8.9% | ||
|
ADAR1 Capital Management, LLC
13G/A
Amendment 3
|
9.9% |
5/15/2026
Event 3/31/2026
|
|
| ADAR1 Capital Management, LLC | 9.9% | ||
| ADAR1 Capital Management GP, LLC | 8.5% | ||
| Daniel Schneeberger | 9.9% | ||
|
Perceptive Advisors LLC
13G/A
Amendment 1
|
10.0% |
2/17/2026
Event 12/31/2025
|
|
| Perceptive Advisors LLC | 10.0% | ||
| Joseph Edelman | 10.0% | ||
| Perceptive Life Sciences Master Fund, Ltd. | 10.0% | ||
|
ADAR1 Capital Management, LLC
13G/A
Amendment 2
|
9.9% |
2/17/2026
Event 12/31/2025
|
|
| ADAR1 Capital Management, LLC | 9.9% | ||
| ADAR1 Capital Management GP, LLC | 9.9% | ||
| Daniel Schneeberger | 9.9% | ||
|
Fairmount Funds Management LLC
13G/A
Amendment 2
|
9.9% |
2/17/2026
Event 12/31/2025
|
|
| Fairmount Funds Management LLC | 9.9% | ||
| Fairmount Healthcare Fund II L.P. | 9.9% | ||
| Peter Harwin | 9.9% | ||
| Tomas Kiselak | 9.9% | ||
|
Sands Capital Life Sciences Pulse Fund II, L.P.
13G/A
Amendment 2
|
10.8% |
2/13/2026
Event 12/31/2025
|
|
| Sands Capital Life Sciences Pulse Fund II, L.P. | 10.8% | ||
| Sands Capital Alternatives, LLC | 10.8% | ||
| Sands Frank M. | 10.8% | ||
|
Nantahala Capital Management, LLC
13G/A
Amendment 1
|
5.7% |
2/13/2026
Event 12/31/2025
|
|
| Nantahala Capital Management, LLC | 5.7% | ||
| Wilmot B. Harkey | 5.7% | ||
| Daniel Mack | 5.7% | ||
|
Trails Edge Capital Partners, LP
13G
|
5.1% |
12/31/2025
Event 12/23/2025
|
|
| Trails Edge Capital Partners, LP | 5.1% | ||
| Trails Edge Biotechnology Master Fund, LP | 5.1% | ||
| Ortav Yehudai | 5.1% | ||
|
ADAR1 Capital Management, LLC
13G/A
Amendment 1
|
9.9% |
8/14/2025
Event 6/30/2025
|
|
| ADAR1 Capital Management, LLC | 9.9% | ||
| ADAR1 Capital Management GP, LLC | 9.9% | ||
| Daniel Schneeberger | 9.9% | ||
|
Sands Capital Life Sciences Pulse Fund II, L.P.
13G/A
Amendment 1
|
14.7% |
8/13/2025
Event 6/30/2025
|
|
| Sands Capital Life Sciences Pulse Fund II, L.P. | 14.7% | ||
| Sands Capital Alternatives, LLC | 14.7% | ||
| Sands Frank M. | 14.7% | ||
|
Armistice Capital, LLC
13G/A
Amendment 1
|
4.99% |
2/14/2025
Event 12/31/2024
|
|
| Armistice Capital, LLC | 4.99% | ||
| Steven Boyd | 4.99% | ||
|
ADAR1 Capital Management, LLC
13G
|
10.0% |
2/14/2025
Event 12/31/2024
|
|
| ADAR1 Capital Management, LLC | 10.0% | ||
| ADAR1 Capital Management GP, LLC | 10.0% | ||
| Daniel Schneeberger | 10.0% | ||
|
Nantahala Capital Management, LLC
13G
|
7.5% |
2/14/2025
Event 12/31/2024
|
|
| Nantahala Capital Management, LLC | 7.5% | ||
| Wilmot B. Harkey | 7.5% | ||
| Daniel Mack | 7.5% | ||
|
Fairmount Funds Management LLC
13G/A
Amendment 1
|
9.9% |
2/14/2025
Event 12/31/2024
|
|
| Fairmount Funds Management LLC | 9.9% | ||
| Fairmount Healthcare Fund II L.P. | 9.9% | ||
| Peter Harwin | 9.9% | ||
| Tomas Kiselak | 9.9% | ||
|
Point72 Asset Management, L.P.
13G/A
Amendment 1
|
0% |
2/14/2025
Event 12/31/2024
|
|
| Point72 Asset Management, L.P. | 0% | ||
| Point72 Capital Advisors, Inc. | 0% | ||
| Steven A. Cohen | 0% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 2 | 1.58 k | $3.25 k |
| 2026 Q2 | 109 | 124 M | $254 M |
| 2026 Q1 | 106 | 118 M | $198 M |
| 2025 Q4 | 75 | 106 M | $218 M |
| 2025 Q3 | 56 | 55.0 M | $89.1 M |
| 2025 Q2 | 50 | 54.5 M | $106 M |
| 2025 Q1 | 48 | 51.5 M | $113 M |
| 2024 Q4 | 33 | 50.1 M | $163 M |
| 2024 Q3 | 12 | 860 k | $1.12 M |
| 2024 Q2 | 14 | 838 k | $1.02 M |
| 2024 Q1 | 15 | 209 k | $451 k |
| 2023 Q4 | 13 | 237 k | $301 k |
| 2023 Q3 | 14 | 430 k | $598 k |
| 2023 Q2 | 15 | 747 k | $2.69 M |
| 2023 Q1 | 1 | 82.8 k | $54.5 k |